Skip to main content

Zura Bio Ltd

corporate_fare Company Profile

Zura Bio Ltd

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed ZURA - Latest Insights

ZURA
Mar 19, 2026, 4:11 PM EDT
Filing Type: 10-K
Importance Score:
8
ZURA
Mar 19, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
ZURA
Mar 10, 2026, 6:40 AM EDT
Filing Type: 8-K
Importance Score:
8
ZURA
Mar 02, 2026, 5:55 PM EST
Filing Type: 4
Importance Score:
8
ZURA
Mar 02, 2026, 5:53 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
ZURA
Feb 25, 2026, 6:51 PM EST
Filing Type: 8-K
Importance Score:
8
ZURA
Feb 25, 2026, 5:06 PM EST
Filing Type: 424B5
Importance Score:
8
ZURA
Feb 24, 2026, 4:29 PM EST
Filing Type: 424B5
Importance Score:
7
ZURA
Feb 23, 2026, 6:40 AM EST
Filing Type: 8-K
Importance Score:
8
ZURA
Jan 27, 2026, 5:19 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
ZURA
Jan 23, 2026, 6:21 PM EST
Filing Type: 8-K
Importance Score:
9
ZURA
Jan 12, 2026, 6:45 AM EST
Filing Type: 8-K
Importance Score:
7
ZURA
Jan 02, 2026, 4:21 PM EST
Filing Type: 8-K
Importance Score:
8